本帖最后由 maicon08 于 2023-4-28 15:12 编辑
1 J/ K) u1 r- U4 _, o! e
+ ~9 O3 \; S4 Q; q3 k1 b一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。& \, F' p( s: N1 w
) c8 w6 i' U) d
https://www.163.com/dy/article/I3BTTPRD053438SI.html; `) P- e3 W. J S" V
5 d$ q$ }1 k) V6 \
8 |) |* I) R3 ?' Z在研疗法-免疫治疗0 l! c9 o; d7 r/ S0 c! F
Developmental Therapeutics—Immunotherapy5 W" h5 c$ ?1 O+ l9 P3 J1 I/ J
% ?: I, r& }% b" D3 r6 C: z摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心 & P) z% a" `5 A% p3 E
在研疗法-分子靶向药物和肿瘤生物学
, [& i+ ^7 P! @ Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 9 l$ Y( [6 A' `+ ^/ R2 ^3 g
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
2 T: p* G/ C5 D. @5 w
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院
- A1 r. R6 a8 ^: I: u0 h
胃肠道肿瘤-结直肠癌和肛门癌 e5 ~/ C# |) n$ J5 ~
Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院
7 g4 L2 ^5 p3 A9 L* l& X- w( T
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
! {, z. F1 T) \摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心
+ r+ Z: z8 V1 g% I# W" n4 Y) c; m
妇科肿瘤 Gynecologic Cancer : _* t) I% o2 K. N! P
摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院
' J% v2 {6 Q/ o! ^, ]1 l" S
头颈肿瘤. y& p0 T$ m0 Y0 q
Head and Neck Cancer 6 ^# ?* u1 H- j4 e ^% t
摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
$ w/ O# ^# z3 v* P9 G
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心
- @+ E0 A$ [ P' H9 e/ e/ S" \
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 + d; W* _ J! I" Q4 f+ R
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
5 [' f4 h; C+ I: `1 v7 \摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心 % i1 V, N+ s; p, X3 M5 F" g* M( b
血液系统恶性肿瘤-浆细胞疾病5 b% w( T' H% E& `
Hematologic Malignancies—Plasma Cell Dyscrasia * e# G2 P! c0 t" B0 ?2 U) U
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院
# i' B9 W" e, v. J/ q: F _0 t
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
1 }2 S& I) j8 u6 @ Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers : N) K% ?) M1 c* a4 `
摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 ' r9 }/ n) v( M+ [/ k
肺癌-转移性非小细胞肺癌
- x6 o. q! L; k1 Y, f Lung Cancer—Non-Small Cell Metastatic # _% }9 m* n' @$ i* }
摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
$ P" ]& v6 h, t8 C1 Q
" D" p7 u+ R `2 W
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院 . S) t- i U! q* S
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院
8 y. K, v. F! C
黑色素瘤/皮肤癌
/ a9 x5 a' ]4 d Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院
: |0 B+ E' f0 F* n( T' p7 _, k
快速摘要报告
9 t* ~- l$ j: S( I Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心 4 J3 T% B# W9 J4 P6 I
临床科学研讨会
4 q! S0 F* L: q: O2 K. u" H8 | Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
5 e3 O. l5 M7 j. N7 B
. H9 y7 b9 v4 D, r9 _& R | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
